查詢結果分析
相關文獻
- Treatment Benefit Analysis for Patients Older Than 80 Years of Age with Clinical Stage II or III Rectal Cancer
- Complicated Urinary Tract Infection: Analysis of 179 Patients
- Prognostic Factors in Node-Negative Breast Cancer Patients: The Experience in Taiwan
- Reentry of a Treated Advanced Periodontal Lesion with an Acute Abscess--A Case Report
- Postoperative Radiotherapy of Adult Supratentorial High-grade Astrocytoma
- Prenatal Diagnosis and Perinatal Outcome of Facial Clefts
- Shock in the Pediatric Emergency Service: Five Years' Experience
- 糖尿病與腦中風
- The Prognostic Significance of Pathologic Characteristics of Breast Cancer Patients in Taiwan
- 以免疫組織化學法則測定膀胱移行上皮癌組織胚胎抗原(CEA)在臨床病理的相關性
頁籤選單縮合
題 名 | Treatment Benefit Analysis for Patients Older Than 80 Years of Age with Clinical Stage II or III Rectal Cancer=高齡臨床分期第2、3期直腸癌治療選項相關預後的分析 |
---|---|
作 者 | 呂宗儒; 陳莊偉; 蕭光宏; | 書刊名 | 中華民國大腸直腸外科醫學會雜誌 |
卷 期 | 29:1 2018.03[民107.03] |
頁 次 | 頁15-21 |
分類號 | 416.245 |
關鍵詞 | 高齡直腸癌; 治療選項; 預後; Rectal cancer; Elderly patient; |
語 文 | 英文(English) |
中文摘要 | 目的:大腸直腸癌的發病率隨著年齡的增長而增加,其中針對直腸癌的治療包括手術切除、化學療法和放射治療。然而,老年是所有治療的重要風險而且具有較高的合併症和死亡率。此外,老年患者除了癌症之外,還會遇到其他內外科嚴重疾病及導致的死亡。在本文中,我們收集80歲以上患者的資料,並分析相關治療選擇的生存獲益及死亡統計。方法:回顧分析了我院2007年至2015年診斷為臨床分期第2或3期直腸癌的台北慈濟醫院病人的病歷資料,對患者的臨床特徵、治療選擇、預後及死亡病因進行比較分析。結果:診斷為臨床分期第2或3期組織學確診直腸癌29例,29例患者中有18例在80~84歲之,8例在85~90歲之間,3例患者90歲以上。55%的患者擁有兩種以上的重大內科疾病,75%的患者追蹤期間死亡,在死亡的患者中,有57.1%的患者死於癌症相關因素。經多變量cox回歸分析,只有術後輔助化療具有統計學生存益處。結論:在高齡直腸癌患者的治療方式上,有接受輔助化學治療(口服5FU)有較好的預後且沒有重大併發症。 |
英文摘要 | Background and purpose. The incidence of colorectal cancer increases with age and treatment of rectal cancer includes surgical resection, total mesorectal excision, chemotherapy, and radiotherapy. However, old age is an important risk for all treatment and has higher rates of comorbidity and mortality. Moreover, those older patients will also encounter other severe disease in their remaining life besides cancer. In this article, we investigate the outcome of patients older than 80-year-old and analyze that survival benefit of treatment. Methods. We retrospectively reviewed the medical records of patients in our section of Taipei Tzu Chi Hospital who was diagnosed as clinical stage II or III rectal cancer from 2007 to 2015. We compared and analyzed the patients' clinical characteristics, treatment choice, outcome, and death etiology. Results. 29 cases were diagnosed as clinical stage II or III histologically-confirmed rectal cancer. 18 of 29 patients were between 80~84 years of age, 8 were between 85~90 years old, and 3 patients were older than 90 years. 55% of patients had more than two systemic comorbid illnesses. 75% patients died during follow-up. Of those patients who died, 57.1% had deaths recorded as being due to their cancer. multivariate cox regression analysis demonstrates that only adjuvant chemotherapy has survival benefit. Conclusions. We conclude that the administration of oral chemotherapy is feasible and has survival benefit in patients older than 80-year-old with clinical stage II or III rectal cancer. |
本系統中英文摘要資訊取自各篇刊載內容。